We are using cookies This website uses cookies in order to offer you the most relevant information. By browsing this website, you accept these cookies.
Did you know? You can double click on a word to look it up on TermGallery.
Meanings of metastatic castration in anglès
We have no meanings for "metastatic castration" in our records yet.
Usage of metastatic castration in anglès
1
We assessed orteronel in chemotherapy-naive patients with metastaticcastration-resistant prostate cancer.
2
The drug is already approved to treat metastaticcastration-resistant prostate cancer.
3
Conclusions: Sorafenib has moderate activity as a second-line treatment for metastaticcastration-resistant prostate cancer.
4
A more reliable tumor marker is needed as a prognostic indicator in metastaticcastration-resistant prostate cancer.
5
This study examined orteronel in patients with metastaticcastration-resistant prostate cancer that progressed after docetaxel therapy.
6
Background: The optimal sequence of life-extending therapies in metastaticcastration-resistant prostate cancer (mCRPC) is unknown.
7
Background: There is a lack of information about the burden of metastaticcastration-resistant prostate cancer (mCRPC).
8
On the basis of these and other data, orteronel is not undergoing further development in metastaticcastration-resistant prostate cancer.
9
Assessment of treatment efficacy in metastaticcastration-resistant prostate cancer (mCRPC) is limited by frequent nonmeasurable bone metastases.
10
Objectives: The independent prognostic effect of comorbidities on outcomes in men with metastaticcastration-resistant prostate cancer (mCRPC) is unclear.
11
Introduction: Radium-223 dichloride is the first alpha-particle emitting therapeutic agent approved by FDA and EMA for bone metastaticcastration-resistant prostate cancer.
12
Together, this led sipuleucel-T to be approved and recommended as first-line therapy in various guidelines for treatment of metastaticcastration-resistant prostate cancer.
13
Purpose: Increases in androgen receptor (AR) copy number (CN) can be detected in plasma DNA when patients develop metastaticcastration-resistant prostate cancer.
14
Conclusion: Patients with metastaticcastration-resistant prostate cancer can be dichotomized by a plasma AR CN cut point of 1.92.
15
Conclusion: TP53 GOF mutations may provide a valuable pathway to delineate metastaticcastration-resistant prostate cancer TP53 mutations into therapeutic categories.
16
The new approval is for patients with metastaticcastration-sensitive prostate cancer, while the drug was earlier approved for non metastatic and metastaticcastration-resistant prostate cancer.